JAMA NetworkDiagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review

CLL affects more than 200,000 people in the United States, and it is responsible for approximately 4,410 deaths each year. Approximately two-thirds of patients require treatment at some point. BTK inhibitors such as acalabrutinib, zanubrutinib, ibrutinib, and pirtobrutinib, as well as BCL2 inhibitors such as venetoclax, are examples of highly effective novel targeted agents.